Hannah Y Wen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/858524/publications.pdf

Version: 2024-02-01

		257450	206112
67	2,730	24	48
papers	citations	h-index	g-index

68	68	68	4862
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. Modern Pathology, 2022, 35, 193-201.	5.5	25
2	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. Clinical Cancer Research, 2022, 28, 404-413.	7.0	13
3	Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast. Journal of Clinical Pathology, 2022, 75, 133-136.	2.0	2
4	Supervised machine learning model to predict oncotype DX risk category in patients over age 50. Breast Cancer Research and Treatment, 2022, 191, 423-430.	2.5	6
5	Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncology, 2022, 8, 607.	7.1	147
6	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. Npj Breast Cancer, 2022, 8, 37.	5.2	9
7	Quality Issues in Diagnostic Immunohistochemistry in Breast Pathology. Pathobiology, 2022, , 1-10.	3.8	2
8	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nature Medicine, 2022, 28, 946-957.	30.7	50
9	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	4.6	21
10	<scp>Wholeâ€exome</scp> sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. Journal of Pathology: Clinical Research, 2021, 7, 113-120.	3.0	4
11	Nextâ€generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline. Histopathology, 2021, 78, 498-507.	2.9	7
12	Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype. Annals of Surgical Oncology, 2021, 28, 4256-4262.	1.5	5
13	Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. Archives of Pathology and Laboratory Medicine, 2021, 145, 1132-1137.	2.5	11
14	Morphologic and immunohistochemical features of carcinoma involving microglandular adenosis of the breast following neoadjuvant chemotherapy. Modern Pathology, 2021, 34, 1310-1319.	5.5	3
15	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. Npj Breast Cancer, 2021, 7, 43.	5.2	16
16	Perineural invasion as a risk factor for locoregional recurrence of invasive breast cancer. Scientific Reports, 2021, 11, 12781.	3.3	17
17	Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. Modern Pathology, 2021, 34, 1850-1859.	5.5	3
18	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. Npj Breast Cancer, 2021, 7, 96.	5.2	38

#	Article	IF	Citations
19	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology, 2021, 34, 2130-2140.	5.5	14
20	Breast conservation among older patients with earlyâ€stage breast cancer: Locoregional recurrence following adjuvant radiation or hormonal therapy. Cancer, 2021, 127, 1749-1757.	4.1	11
21	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discovery, 2021, 11, 1212-1227.	9.4	139
22	HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern. Archives of Pathology and Laboratory Medicine, 2021, 145, 979-987.	2.5	7
23	Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results. Cancers, 2021, 13, 6273.	3.7	9
24	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathology, 2020, 33, 354-366.	5.5	25
25	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number â‰¥4.0 and <6.0. Archives of Pathology and Laboratory Medicine, 2020, 144, 597-601.	2.5	10
26	Immunohistochemical assessment ofHRASQ61R mutations in breast adenomyoepitheliomas. Histopathology, 2020, 76, 865-874.	2.9	19
27	A phase 2 clinical trialâ€assessing theâ€efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic tripleâ€negative breast cancer. Cancer, 2020, 126, 850-860.	4.1	116
28	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. Modern Pathology, 2020, 33, 1056-1064.	5.5	35
29	The genomic landscape of metastatic histologic special types of invasive breast cancer. Npj Breast Cancer, 2020, 6, 53.	5.2	27
30	Wholeâ€exome analysis of metaplastic breast carcinomas with extensive osseous differentiation. Histopathology, 2020, 77, 321-326.	2.9	7
31	Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia. Breast Cancer Research and Treatment, 2020, 184, 873-880.	2.5	8
32	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. Journal of Clinical Pathology, 2020, , jclinpath-2020-207052.	2.0	5
33	Multigene testing in breast cancer: What have we learned from the 21â€gene recurrence score assay?. Breast Journal, 2020, 26, 1199-1207.	1.0	8
34	Extranodal Tumor Deposits in the Axillary Fat Indicate the Need for Axillary Dissection Among T1â€“T2cN0 Patients with Positive Sentinel Nodes. Annals of Surgical Oncology, 2020, 27, 3585-3592.	1.5	9
35	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. Npj Breast Cancer, 2020, 6, 20.	5.2	25
36	Whole-Exome Sequencing Analysis of the Progression from Nonâ€“Low-Grade Ductal CarcinomaIn Situto Invasive Ductal Carcinoma. Clinical Cancer Research, 2020, 26, 3682-3693.	7.0	42

#	Article	IF	Citations
37	Homologous recombination DNA repair defects in PALB2-associated breast cancers. Npj Breast Cancer, 2019, 5, 23.	5.2	39
38	Wholeâ€exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. Histopathology, 2019, 75, 931-937.	2.9	16
39	TOX is a critical regulator of tumour-specific T cell differentiation. Nature, 2019, 571, 270-274.	27.8	697
40	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. Nature Communications, 2019, 10, 4369.	12.8	18
41	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. Npj Breast Cancer, 2019, 5, 6.	5.2	21
42	Reply to â€œMulticentric Ipsilateral Invasive Breast Carcinomas Might Have Higher 21-Gene Recurrence Score Compared with Multifocal Ipsilateral Invasive Breast Carcinomasâ€• Annals of Surgical Oncology, 2019, 26, 310-311.	1.5	1
43	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. JNCI Cancer Spectrum, 2019, 3, pkz027.	2.9	20
44	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Research and Treatment, 2019, 177, 61-66.	2.5	42
45	Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system. Breast Journal, 2019, 25, 829-837.	1.0	9
46	Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. Histopathology, 2019, 75, 213-224.	2.9	46
47	Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. Histopathology, 2019, 75, 139-145.	2.9	22
48	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern Pathology, 2019, 32, 81-87.	5.5	10
49	The Genomic Landscape of Mucinous Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 737-741.	6.3	68
50	Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?. Annals of Surgical Oncology, 2019, 26, 329-335.	1.5	9
51	The 21-Gene Recurrence Score in Male Breast Cancer. Annals of Surgical Oncology, 2018, 25, 1530-1535.	1.5	14
52	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. Journal of the National Cancer Institute, 2018, 110, 1030-1034.	6.3	90
53	Precise pathologic diagnosis and individualized treatment improve the outcomes of invasive micropapillary carcinoma of the breast: a 12-year prospective clinical study. Modern Pathology, 2018, 31, 956-964.	5.5	21
54	Lobular Carcinoma In Situ. Surgical Pathology Clinics, 2018, 11, 123-145.	1.7	58

#	Article	IF	Citations
55	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. BMC Cancer, 2018, 18, 42.	2.6	9
56	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications, 2018, 9, 1816.	12.8	105
57	Breast Cancers of Special Histologic Subtypes Are Biologically Diverse. Annals of Surgical Oncology, 2018, 25, 3158-3164.	1.5	26
58	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. Nature Medicine, 2017, 23, 376-385.	30.7	111
59	Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2017, 24, 2556-2562.	1.5	45
60	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. Breast Cancer Research and Treatment, 2017, 165, 65-76.	2.5	28
61	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 166, 69-76.	2.5	31
62	Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical followâ€up. Cancer, 2017, 123, 131-137.	4.1	16
63	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Modern Pathology, 2017, 30, 69-84.	5.5	48
64	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Modern Pathology, 2016, 29, 476-488.	5.5	95
65	Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3030-3035.	7.1	52
66	Somatic mutations in leukocytes infiltrating primary breast cancers. Npj Breast Cancer, 2015, 1, 15005.	5.2	30
67	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. Histopathology, 2015, 67, 529-537.	2.9	37